Free Trial

Lbp Am Sa Increases Holdings in Stryker Corporation (NYSE:SYK)

Stryker logo with Medical background

LBP AM SA lifted its position in Stryker Corporation (NYSE:SYK - Free Report) by 11.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 228,469 shares of the medical technology company's stock after purchasing an additional 22,659 shares during the quarter. Stryker accounts for approximately 1.3% of LBP AM SA's holdings, making the stock its 15th biggest holding. LBP AM SA owned approximately 0.06% of Stryker worth $85,048,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in SYK. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Assetmark Inc. raised its holdings in Stryker by 28.1% during the 4th quarter. Assetmark Inc. now owns 1,298 shares of the medical technology company's stock worth $467,000 after buying an additional 285 shares during the period. Proficio Capital Partners LLC grew its stake in shares of Stryker by 46.2% during the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock worth $596,000 after acquiring an additional 523 shares in the last quarter. NBT Bank N A NY grew its stake in shares of Stryker by 20.1% during the 4th quarter. NBT Bank N A NY now owns 4,240 shares of the medical technology company's stock worth $1,527,000 after acquiring an additional 709 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its stake in shares of Stryker by 5.9% during the 4th quarter. Daiwa Securities Group Inc. now owns 51,886 shares of the medical technology company's stock worth $18,682,000 after acquiring an additional 2,883 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

SYK has been the subject of several analyst reports. Truist Financial raised their target price on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. Citigroup reaffirmed a "buy" rating and issued a $455.00 price target (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. BTIG Research set a $403.00 price target on Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Roth Mkm boosted their target price on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Sanford C. Bernstein set a $450.00 target price on Stryker in a research note on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $428.55.

Check Out Our Latest Report on SYK

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director directly owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.90% of the company's stock.

Stryker Trading Up 1.0%

Shares of Stryker stock traded up $3.73 on Thursday, reaching $395.78. 315,440 shares of the company's stock were exchanged, compared to its average volume of 1,459,770. The company has a market capitalization of $151.06 billion, a P/E ratio of 53.49, a price-to-earnings-growth ratio of 2.94 and a beta of 0.91. Stryker Corporation has a 52 week low of $314.93 and a 52 week high of $406.19. The firm's 50-day moving average is $384.17 and its two-hundred day moving average is $376.78. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the firm earned $2.50 earnings per share. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. Sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Monday, June 30th. Stryker's payout ratio is currently 45.41%.

Stryker Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines